Joanna M Wardlaw Selected Research

Nitric Oxide Donors

1/2020	Intracranial Bleeding After Reperfusion Therapy in Acute Ischaemic Stroke Patients Randomized to Glyceryl Trinitrate vs. Control: An Individual Patient Data Meta-Analysis.
1/2019	Baseline characteristics of the 1149 patients recruited into the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) randomized controlled trial.
6/2018	Statistical analysis plan for the 'Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)'.
1/2016	Effect of Treatment Delay, Stroke Type, and Thrombolysis on the Effect of Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome after Acute Stroke: A Systematic Review and Meta-Analysis of Individual Patient from Randomised Trials.
1/2016	Glyceryl Trinitrate for Acute Intracerebral Hemorrhage: Results From the Efficacy of Nitric Oxide in Stroke (ENOS) Trial, a Subgroup Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joanna M Wardlaw Research Topics

Disease

86	Stroke (Strokes) 10/2022 - 05/2004
52	Ischemic Stroke 02/2022 - 04/2005
16	Cognitive Dysfunction 02/2022 - 06/2005
14	Dementia (Dementias) 02/2022 - 01/2012
13	Hypertension (High Blood Pressure) 01/2022 - 10/2010
13	Cerebral Small Vessel Diseases 01/2021 - 12/2010
8	Inflammation (Inflammations) 01/2022 - 02/2014
8	Hemorrhage 10/2021 - 10/2009
8	Alzheimer Disease (Alzheimer's Disease) 06/2021 - 04/2012
8	Atrophy 12/2015 - 06/2005
7	Cerebral Hemorrhage 10/2021 - 01/2016
7	Lacunar Stroke 01/2021 - 10/2014
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2016
4	Infarction (Infarctions) 01/2021 - 06/2015
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 05/2004
3	Carotid Stenosis (Carotid Artery Stenosis) 03/2019 - 06/2002
3	Thrombosis (Thrombus) 10/2018 - 01/2016
2	Disease Progression 01/2022 - 03/2021
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022 - 01/2021
2	Atherosclerosis 01/2022 - 12/2016
2	Headache (Headaches) 10/2021 - 01/2020
2	Mood Disorders (Mood Disorder) 06/2021 - 06/2021
2	Frailty 12/2020 - 01/2020
2	Brain Diseases (Brain Disorder) 01/2018 - 07/2006
2	Hypercholesterolemia 01/2017 - 10/2010
2	Infections 02/2016 - 08/2013
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 08/2015 - 03/2015
2	Substance-Related Disorders (Drug Abuse) 06/2013 - 01/2010
2	Bipolar Disorder (Manic Depressive Psychosis) 06/2013 - 01/2010
1	Aortic Valve Stenosis (Aortic Stenosis) 01/2022
1	Myocardial Infarction 01/2022
1	Osteoporosis 01/2022
1	Parkinson Disease (Parkinson's Disease) 01/2022
1	Vascular Diseases (Vascular Disease) 10/2021
1	Vascular Remodeling 10/2021
1	Peripheral Arterial Disease 10/2021
1	Pathologic Constriction (Stenosis) 01/2021
1	Encephalitis (Encephalitis, Rasmussen) 01/2021
1	Birth Weight (Birth Weights) 01/2021
1	Major Depressive Disorder (Major Depressive Disorders) 01/2021
1	Hemorrhagic Stroke 01/2020

Drug/Important Bio-Agent (IBA)

25	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 04/2005
20	Biomarkers (Surrogate Marker)IBA 02/2022 - 09/2010
13	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2022 - 08/2014
12	Nitroglycerin (Dynamite)FDA LinkGeneric 10/2022 - 01/2016
9	Retinaldehyde (Retinal)IBA 01/2020 - 10/2010
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2016
7	Cilostazol (Pletal)FDA LinkGeneric 01/2022 - 01/2018
6	salicylhydroxamic acid (SHAM)IBA 10/2022 - 06/2015
5	LipidsIBA 10/2021 - 11/2015
5	Nitric Oxide DonorsIBA 01/2020 - 01/2016
5	SaltsIBA 01/2018 - 10/2011
5	Apolipoproteins E (ApoE)IBA 01/2017 - 01/2013
4	Amyloid (Amyloid Fibrils)IBA 02/2022 - 01/2021
4	isosorbide-5-mononitrate (Ismo)FDA LinkGeneric 01/2022 - 01/2018
4	ORALIT (ORS)IBA 01/2022 - 06/2012
4	IronIBA 03/2019 - 03/2012
4	CholesterolIBA 01/2019 - 11/2015
3	Antihypertensive Agents (Antihypertensives)IBA 02/2022 - 05/2016
3	Pharmaceutical PreparationsIBA 10/2021 - 10/2009
3	Biological ProductsIBA 10/2020 - 12/2009
3	GadoliniumIBA 01/2017 - 04/2008
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 07/2014 - 10/2009
3	Hydrocortisone (Cortisol)FDA LinkGeneric 06/2013 - 06/2005
3	Protons (Proton)IBA 02/2010 - 07/2006
3	Lactic Acid (Lactate)FDA LinkGeneric 02/2010 - 03/2009
2	C-Reactive ProteinIBA 12/2021 - 12/2016
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2021 - 01/2020
2	Clopidogrel (Plavix)FDA Link 10/2021 - 01/2020
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 06/2021 - 06/2021
2	Glucose (Dextrose)FDA LinkGeneric 06/2021 - 06/2021
2	Contrast MediaIBA 01/2020 - 05/2009
2	LDL CholesterolIBA 01/2017 - 11/2015
2	ApolipoproteinsIBA 01/2017 - 06/2014
2	Fibrinogen (Factor I)FDA Link 12/2016 - 03/2012
2	Interleukin-6 (Interleukin 6)IBA 12/2016 - 08/2013
2	Poly TIBA 12/2015 - 01/2013
2	LithiumIBA 06/2013 - 01/2010
2	N-acetylaspartate (N-acetyl aspartate)IBA 03/2009 - 10/2006
1	DiamondIBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	CalciumIBA 01/2022
1	FluoridesIBA 01/2022
1	Type 3 Cyclic Nucleotide PhosphodiesterasesIBA 10/2021
1	AnticoagulantsIBA 10/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Phosphodiesterase 3 InhibitorsIBA 01/2020
1	Vasodilator Agents (Vasodilators)IBA 11/2019
1	benzo(g)isoquinoline-5,10-dione (BGID)IBA 03/2019
1	ferric oxide (iron oxide)IBA 02/2019

Therapy/Procedure

21	Therapeutics 02/2022 - 04/2002
6	Secondary Prevention 10/2021 - 11/2015
4	Thrombolytic Therapy 01/2016 - 03/2009
3	Thrombectomy 01/2020 - 11/2015
3	Induced Hypothermia 09/2019 - 10/2012
2	Contraindications 01/2019 - 08/2015
2	Time-to-Treatment 01/2016 - 10/2009
2	Treatment Delay 01/2016 - 01/2016
2	Endarterectomy (Thromboendarterectomy) 11/2009 - 06/2002
1	Carotid Endarterectomy 01/2021